Company Description
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally.
The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization.
In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers.
Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions.
The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations.
ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.
| Country | Ireland |
| Founded | 1990 |
| IPO Date | May 15, 1998 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 41,100 |
| CEO | Steven Cutler |
Contact Details
Address: South County Business Park, Leopardstown Dublin, D18 X5R3 Ireland | |
| Phone | 353 1 291 2000 |
| Website | iconplc.com |
Stock Details
| Ticker Symbol | ICLR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001060955 |
| CUSIP Number | G4705A100 |
| ISIN Number | IE0005711209 |
| Employer ID | 98-1067160 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Dr. Steven A. Cutler MBA, Ph.D. | Chief Executive Officer and Director |
| Dr. John Climax Ph.D. | Founder and Independent Non-Executive Director |
| Thomas N. O'Leary | Chief Information Officer |
| Diarmaid Cunningham | Chief Administrative Officer, General Counsel and Company Secretary |
| Niamh Murphy | Director of Corporate Communications |
| David Green | Vice President of Marketing |
| Joe Cronin | Chief Human Resources Officer |
| Simon Holmes | President of Corporate Investments and Partnerships |
| Dr. Gary Curtis | Senior Vice President of Global Clinical Pharmacology |
| Dr. Peter Schueler | Senior Vice President of Drug Development Services - CNS |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 13, 2024 | 6-K | Report of foreign issuer |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 25, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Oct 25, 2024 | 6-K | Report of foreign issuer |
| Oct 23, 2024 | 6-K | Report of foreign issuer |
| Sep 27, 2024 | 6-K | Report of foreign issuer |
| Sep 3, 2024 | 6-K | Report of foreign issuer |
| Aug 26, 2024 | 144 | Filing |
| Aug 14, 2024 | 6-K | Report of foreign issuer |
| Jul 30, 2024 | 144 | Filing |